Iambic Therapeutics Secures $100M in Series B Financing to Propel AI-Driven Drug Discovery and Clinical Advancements.
Iambic Therapeutics, established post-2021 Series A financing, focuses on leveraging AI to expedite the delivery of therapeutics across various target classes and mechanisms of action.
Company Name: Iambic Therapeutics (formerly known as Entos)
Location: San Diego, CA
Sector: Biotechnology, AI-Driven Drug Discovery
Funding Details: Closed a $100m Series B financing, co-led by Ascenta Capital and Abingworth. Participants included NVIDIA, Illumina Ventures, Gradiant Corporation, with support from independent board member Bill Rastetter. Existing investors like Nexus Ventures, Catalio Capital Management, Coatue, FreeFlow, OrbiMed, and Sequoia Capital also contributed.
Purpose of Investment: To advance multiple candidates into clinical development, expand the pipeline with additional candidates, and continue innovating next-generation AI and automation technologies for drug discovery.
Leadership: Co-founder and CEO Tom Miller, Ph.D.
Product: AI-driven drug-discovery platform for developing novel therapeutics. The platform unifies physics-informed machine learning with experimental automation.
About Company: Iambic Therapeutics, established post-2021 Series A financing, focuses on leveraging AI to expedite the delivery of therapeutics across various target classes and mechanisms of action. The company has made significant strides in AI-driven drug discovery, showcasing its platform's effectiveness in identifying candidates with distinct drug profiles.
Key Innovations:
- Development of an AI-driven discovery platform combining machine learning and experimental automation.
- Utilization of NVIDIA's technology, including the NVIDIA DGX Cloud AI supercomputing platform and NVIDIA BioNeMo cloud service.
Clinical Developments:
- IAM-H1: A selective and brain-penetrant inhibitor of HER2 and its oncogenic mutants.
- IAM-C1: A potential first-in-class selective dual CDK2/4 inhibitor for cell-cycle-driven cancers.
